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A B S T R A C T
Doxorubicin (DOX) is one of the most widely used anti-neoplastic agents. However, treatment with DOX is
associated with cumulative cardiotoxicity inducing progressive cardiomyocyte death. Sirtuin 3 (Sirt3), a mi-
tochondrial deacetylase, regulates the activity of proteins involved in apoptosis, autophagy and metabolism. Our
hypothesis is that pharmacological modulation by berberine (BER) pre-conditioning of Sirt3 protein levels de-
creases DOX-induced cardiotoxicity. Our results showed that DOX induces cell death in all experimental groups.
Increase in Sirt3 content by transfection-mediated overexpression decreased DOX cytotoxicity, mostly by
maintaining mitochondrial network integrity and reducing oxidative stress. p53 was upregulated by DOX, and
appeared to be a direct target of Sirt3, suggesting that Sirt3-mediated protection against cell death could be
related to this protein. BER pre-treatment increased Sirt3 and Sirt1 protein levels in the presence of DOX and
inhibited DOX-induced caspase 9 and 3-like activation. Moreover, BER modulated autophagy in DOX-treated
H9c2 cardiomyoblasts. Interestingly, mitochondrial biogenesis markers were upregulated in in BER/DOX-treated
cells. Sirt3 over-expression contributes to decrease DOX cytotoxicity on H9c2 cardiomyoblasts, while BER can be
used as a modulator of Sirtuin function and cell quality control pathways to decrease DOX toxicity.
1. Introduction
The anthracycline Doxorubicin (DOX) is one of the most prescribed
and eﬀective anti-cancer agents [1,2]. The clinical use of DOX has been
associated with a cumulative and dose-speciﬁc cardiotoxicity that in-
volves the development of congestive heart failure [3–6]. Being a very
potent chemotherapeutic, a more eﬀective prevention of DOX-induced
cardiotoxicity is needed in order to potentially optimize the eﬀective
dosage given to patients and therefore reduce morbidity.
Adult cardiac progenitor cells (CPCs), present in adult heart, contain
stem cell characteristics and are involved in tissue homeostasis and
myocardial regeneration during pathological conditions [7–9]. CPCs
have been studied in the context of several pathological conditions in
animal and humans including as a pathophysiological target against
DOX cardiotoxicity [9–12]. One relevant model to investigate DOX-
induced eﬀects on CPCs is the H9c2 cell line, which has morphological
characteristics similar to immature embryonic cardiomyocytes
[2,13–16].
It has been previously described that DOX, at 0.5 and 1 μM con-
centrations, equivalent to those achieved in the plasma upon adminis-
tration of therapeutic doses [14], promotes metabolic stress and in-
creases protein acetylation of crucial mitochondrial enzymes [17–19].
Sirtuins are NAD+-dependent deacetylases that catalyse the deacety-
lation of histone and non-histone lysine residues, also having protein
ADP-Ribosyltransferase activity [20]. Sirtuin 3 (Sirt3) is the major
mitochondrial deacetylase [21], modulating several mitochondrial
pathways [22]. Sirt3 is involved in the maintenance of oxidative
phosphorylation during stress, regulation of ROS generation at the
electron transport chain (ETC), as well as detoxiﬁcation of ROS via
activation of antioxidant enzymes, such as glutathione and superoxide
dismutase 2 (SOD2) [17,23–25]. Moreover, it was shown that Sirt3 was
capable of deacetylating OPA1, contributed to the preservation of
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